Lack of pharmacokinetic interaction between rilpivirine and integrase inhibitors dolutegravir and GSK1265744. - Wikidata - wikimedia - TriplyDB

Lack of pharmacokinetic interaction between rilpivirine and integrase inhibitors dolutegravir and GSK1265744.

Lack of pharmacokinetic interaction between rilpivirine and integrase inhibitors dolutegravir and GSK1265744.

http://www.wikidata.org/entity/Q37263531

about

Clinical effectiveness of dolutegravir in the treatment of HIV/AIDS Dolutegravir - a review of the pharmacology, efficacy, and safety in the treatment of HIV Pre-exposure prophylaxis to prevent HIV infection: current status, future opportunities and challenges Profile of cabotegravir and its potential in the treatment and prevention of HIV-1 infection: evidence to date Efavirenz Has the Highest Anti-Proliferative Effect of Non-Nucleoside Reverse Transcriptase Inhibitors against Pancreatic Cancer Cells Switch to Dolutegravir plus Rilpivirine Dual Therapy in cART-Experienced Subjects: An Observational Cohort Lack of effect of oral cabotegravir on the pharmacokinetics of a levonorgestrel/ethinyl oestradiol-containing oral contraceptive in healthy adult women Pharmacodynamics of long-acting folic acid-receptor targeted ritonavir-boosted atazanavir nanoformulations.The role of dolutegravir in the management of HIV infection The clinical role and cost-effectiveness of long-acting antiretroviral therapy Clinical pharmacokinetic, pharmacodynamic and drug-interaction profile of the integrase inhibitor dolutegravir.Drug-Drug Interaction between the Direct-Acting Antiviral Regimen of Ombitasvir-Paritaprevir-Ritonavir plus Dasabuvir and the HIV Antiretroviral Agent Dolutegravir or Abacavir plus Lamivudine Effect of Cabotegravir on Cardiac Repolarization in Healthy Subjects.Dolutegravir, a second-generation integrase inhibitor for the treatment of HIV-1 infection.Dolutegravir for the treatment of adult patients with HIV-1 infection.Dolutegravir: a next-generation integrase inhibitor for treatment of HIV infection.Evaluation of dolutegravir safety for the treatment of HIV-1.Influence of nevirapine administration on the pharmacokinetics of dolutegravir in patients infected with HIV-1.Formulation and pharmacology of long-acting cabotegravir.Clinical pharmacokinetics and pharmacodynamics of dolutegravir used as a single tablet regimen for the treatment of HIV-1 infection.Long-Acting Antiretrovirals: Where Are We now?Effectiveness, Safety, and Costs of a Treatment Switch to Dolutegravir Plus Rilpivirine Dual Therapy in Treatment-Experienced HIV Patients.Viral kinetics in semen with different antiretroviral families in treatment-naïve HIV-infected patients: a randomized trial.Pharmacokinetics of dolutegravir and rilpivirine in combination with simeprevir and sofosbuvir in HIV/hepatitis C virus-coinfected patients with liver cirrhosis.Drug interaction profile of the HIV integrase inhibitor cabotegravir: assessment from in vitro studies and a clinical investigation with midazolam.Safety, tolerability and pharmacokinetics of rilpivirine following administration of a long-acting formulation in healthy volunteers.Parenteral antiretroviral formulations are still urgently needed: a case report and commentary.Efficacy and safety of dolutegravir and rilpivirine dual therapy as a simplification strategy: a cohort study.Investigational HIV integrase inhibitors in phase I and phase II clinical trials.HIV-Positive-to-HIV-Positive Liver Transplantation Dolutegravir: a new option for HIV treatment Bioequivalence of a Fixed-Dose Combination Tablet of the Complete Two-Drug Regimen of Dolutegravir and Rilpivirine for Treatment of HIV-1 Infection

P2860

Q26778450-94A2EA36-779B-4068-91CC-7CF6EB3720A6 Q26799712-A508F4D3-5247-4D40-B613-3B8DBCF22F7D Q26825641-A622DB54-9E23-4D1F-9356-D0DCA8C1152C Q28079025-476EE95D-3263-4BC9-99AD-C47F277AED39 Q28548473-677B9756-E6FD-4EC6-83FD-CC5F8BAB0DE5 Q28552719-8F42099D-DF64-4829-8E8D-8C582F0BF258 Q33780895-5F2B115F-BF8B-4E20-A0A9-E5D09240B4B7 Q34745586-139ABA62-FF27-4B2A-9292-1FC8B68E6256 Q35121450-D8BE9B20-D1C0-47A3-9308-621F0C0ADB22 Q35197271-2E517581-FA91-4DC4-A2BF-021139FCD3F4 Q37248656-469E20BC-6247-4039-AFD1-21E428DB7E62 Q37287684-D52066FA-2255-4531-AFF2-7AAFB1B42A2C Q37462061-AC7B1113-D2DF-418B-BFFE-9735CBE5E20F Q38164678-330CFE58-3DE4-4354-B9D0-B8F4449DDA82 Q38201520-03DB360B-D848-49FE-81DC-9385BF402C75 Q38203844-CFBFD9D9-C85C-42F8-A716-60BC8B454990 Q38262935-D6CE20B4-E6DD-4968-AE02-FF9891172A41 Q38405955-E33270F9-0C8B-488D-A7B9-25E712A164BB Q38518434-49F46549-366C-4D8D-A911-9821A83900AC Q38541809-173E0110-6BBE-460A-BB98-CF294FC94BFA Q38902077-39310A69-C0AE-4C45-BF2B-12ED7A28B985 Q40072531-206D58AC-1FEC-465B-907C-8A05289FABB9 Q40225129-68B865D8-B4F0-42B9-BE16-46701773FAE3 Q40401740-86838802-0673-4334-B72C-57FB7AFDB846 Q41015337-F60DB2B3-DA24-4D48-AC4E-C60A0BBF9FF9 Q41219268-503A3558-42D1-480E-8CB2-1AD6238AB367 Q42212544-C9FA7569-10A0-4559-89E5-7D58EF16F769 Q47800071-DEA7607B-A444-478F-B225-FC8B5EF43899 Q47909110-57AF6BD1-9C03-4F1E-8B63-1D46F0347D05 Q56520909-41EB63C0-C66D-4E02-B5FF-C49BC013C1D7 Q58290460-FEA918E9-7AF2-42CE-89AA-356B8EF50F45 Q58700561-06F912F6-EE89-4770-B708-622C9D4359D6

P2860

Lack of pharmacokinetic interaction between rilpivirine and integrase inhibitors dolutegravir and GSK1265744.

http://www.wikidata.org/entity/Q37263531

description

article científic

@ca

article scientifique

@fr

articolo scientifico

@it

artigo científico

@pt

bilimsel makale

@tr

scientific article published on 26 August 2013

@en

vedecký článok

@sk

vetenskaplig artikel

@sv

videnskabelig artikel

@da

vědecký článek

@cs

name

Lack of pharmacokinetic intera ...... s dolutegravir and GSK1265744.

@en

Lack of pharmacokinetic intera ...... s dolutegravir and GSK1265744.

@nl

type

label

Lack of pharmacokinetic intera ...... s dolutegravir and GSK1265744.

@en

Lack of pharmacokinetic intera ...... s dolutegravir and GSK1265744.

@nl

prefLabel

Lack of pharmacokinetic intera ...... s dolutegravir and GSK1265744.

@en

Lack of pharmacokinetic intera ...... s dolutegravir and GSK1265744.

@nl

P1433

Q37263531-7F299960-B4D9-430A-AD1E-1C1BE35ECAFD

P1476

Q37263531-D5F91B3C-CB7B-400E-9516-4DC36D3D90C1

P2093

Q37263531-033E63BF-9328-40C0-A9F9-D7BD4D6DA6E6

Q37263531-4AE1C77D-903A-4B04-9D54-1841979438C3

Q37263531-8CB04F8E-02B3-48BE-82D6-64F35707C339

Q37263531-9585A303-3629-43C6-AC1F-7628F7A309B7

Q37263531-C40C6803-EAC0-47C0-94EF-92B57F8A5190

Q37263531-D1A5FE80-B8A3-4EB5-BD4B-B93C67382D35

Q37263531-EB9F4236-9B88-48C2-AB0D-761A3EB58823

P2860

Q37263531-0953AE77-B972-482E-8B80-B4347E04B2BC

Q37263531-1873E0CC-5FDC-465C-BC34-805E7B957A2E

Q37263531-23E20CA1-BB77-4E3A-BB2E-C7E49041FCC8

Q37263531-3B1579DA-6F21-4A3F-95B9-8D4BF6A3C0B0

Q37263531-3F654CE2-9877-433B-98CD-0342169103CF

Q37263531-5D762E5C-93E1-4F67-900D-212F1F03968F

Q37263531-8BF92B99-920D-425C-854F-F8DD1E0BD5D9

Q37263531-933C8608-2AE0-4AE1-9FDB-A1E437E77418

Q37263531-B50196DF-8542-47E4-979B-FEB51ADEE023

Q37263531-D002A5FB-4329-4B89-BDD4-D535E908E60D

P304

Q37263531-81879DE6-2133-40F6-85AD-CE2F2D2C36D4

P31

Q37263531-AC7284DE-F922-42BF-9DD6-E4651DCF2218

P356

Q37263531-C5E3A7FC-5756-4D87-B539-38DDC25E37AD

P407

Q37263531-5F20C95C-0245-41B2-85F6-FD99D2177547

P433

Q37263531-E596E28B-EE1F-44CC-A36C-96F8F96CFAF1

P478

Q37263531-6CD758D1-3F06-4D1B-9E57-F83305D91523

P577

Q37263531-5DAFBCB9-994B-49E2-8DF9-2E6367CC1B80

P698

Q37263531-631B34E7-244E-46ED-B444-BB17465E0198

P932

Q37263531-31AD90EC-17C6-48D8-B023-7A644435D9C0

P356

P1433

Antimicrobial Agents and Chemotherapy

P1476

Lack of pharmacokinetic intera ...... s dolutegravir and GSK1265744.

@en

P2093

David Margolis

http://www.w3.org/2001/XMLSchema#string

Elizabeth Gould

http://www.w3.org/2001/XMLSchema#string

Herta Crauwels

http://www.w3.org/2001/XMLSchema#string

Shuguang Chen

http://www.w3.org/2001/XMLSchema#string

Stephen Piscitelli

http://www.w3.org/2001/XMLSchema#string

Susan L Ford

http://www.w3.org/2001/XMLSchema#string

William Spreen

http://www.w3.org/2001/XMLSchema#string

P2860

Development of a long-acting injectable formulation with nanoparticles of rilpivirine (TMC278) for HIV treatment.

Safety and efficacy of dolutegravir in treatment-experienced subjects with raltegravir-resistant HIV type 1 infection: 24-week results of the VIKING Study.

Effect of atazanavir and atazanavir/ritonavir on the pharmacokinetics of the next-generation HIV integrase inhibitor, S/GSK1349572.

Effects of etravirine on the pharmacokinetics of the integrase inhibitor S/GSK1265744.

Effects of etravirine alone and with ritonavir-boosted protease inhibitors on the pharmacokinetics of dolutegravir.

Pharmacokinetics, safety, and monotherapy antiviral activity of GSK1265744, an HIV integrase strand transfer inhibitor.

Dolutegravir versus raltegravir in antiretroviral-experienced, integrase-inhibitor-naive adults with HIV: week 48 results from the randomised, double-blind, non-inferiority SAILING study.

In vitro investigations into the roles of drug transporters and metabolizing enzymes in the disposition and drug interactions of dolutegravir, a HIV integrase inhibitor.

Lack of interaction between the HIV integrase inhibitor S/GSK1349572 and tenofovir in healthy subjects.

Once-daily dolutegravir versus raltegravir in antiretroviral-naive adults with HIV-1 infection: 48 week results from the randomised, double-blind, non-inferiority SPRING-2 study.

P304

5472-5477

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1128/AAC.01235-13

http://www.w3.org/2001/XMLSchema#string

P407

P433

11

http://www.w3.org/2001/XMLSchema#string

P478

57

http://www.w3.org/2001/XMLSchema#string

P577

2013-08-26T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

23979733

http://www.w3.org/2001/XMLSchema#string

P932

3811315

http://www.w3.org/2001/XMLSchema#string